Clinical Trial Update: Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

A Phase II randomized trial compared GA101 (obinutuzumab) to Rituximab in untreated low tumor burden indolent non-Hodgkin lymphoma; results were posted after th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma

Drugs mentioned

• GA101 (obinutuzumab)
• Rituximab (rituximab)

Snippet

Sponsor: PrECOG, LLC. | Conditions: Indolent Non-Hodgkin's Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2017-05-05